Table 3 Prognostic significance of selected genes in prostate cancer cohorts

TWIST1

2.05

(1.30–3.22)

P = 0.0019

0.95

(0.39–2.35)

P = 0.917

1.46

(0.84–2.54)

P = 0.178

2.69

(1.11–6.49)

P = 0.028

1.72

(1.13–2.60)

P = 0.01

KCNN2

2.39

(1.51–3.79)

P = 0.000216

1.91

(0.75–4.86)

P = 0.17

1.52

(0.87–2.27)

P = 0.14

1.78

(0.78–4.08)

P = 0.17

0.84

(0.56–1.26)

P = 0.41

SPRED1

NA

0.90

(0.36–2.23)

P = 0.81

0.76

(0.44–1.32)

P = 0.33

0.96

(0.43–2.13)

P = 0.91

0.96

(0.64–1.44)

P = 0.85

PPFIBP2

NA

1.21

(0.49–3.02)

P = 0.68

1.73

(0.99–3.03)

P = 0.05

0.86

(0.38–1.92)

P = 0.70

0.76

(0.50–1.13)

P = 0.17

JAG1

1.36

(0.88–2.10)

P = 0.17

2.23

(0.85–5.88)

P = 0.10

2.293

(1.28–4.12)

P = 0.005

1.25

(0.56–2.80)

P = 0.59

1.30

(0.87–1.94)

P = 0.21

IGFBP3

1.00

(0.65–1.55)

P = 0.99

1.09

(0.44–2.68)

P = 0.86

1.56

(0.89–2.73)

P = 0.12

1.99

(0.85–4.66)

P = 0.11

2.07

(1.36–3.20)

P = 0.0008

NDRG1

2.28

(1.43–3.64)

P = 0.0005

1.43

(0.58–3.56)

P = 0.44

0.81

(0.47–1.41)

P = 0.45

0.78

(0.34–1.75)

P = 0.54

0.96

(0.64–1.43)

P = 0.82